SMYD3 and neoplasm: We used the IVIS lumina system to evaluate the effect of combination therapy with BCI‐121 and anti‐PD‐1 antibodies in vivo, and combination therapy further reduced tumor size, indicating that BCI‐121, which inhibits SMYD3 activity, can sensitize tumors to anti‐PD‐1 therapy, thus producing a synergistic effect (Figure 7H,I).